Balanced Pharma Inc. (BPI), based in North Carolina, USA, recently announced that Septodont of France has made a strategic investment in it to support the development of its novel dental injectable drugs.
BPI also said that Atif Zia, chief operating officer of Septodont, has joined its board of directors.
“We are very proud to add Septodont to the growing list of members of the dental industry, invest in the development of these important products, and have Atif [Zia] become a member of our leadership team,” said Dr. Scott Keadle, retired dentist and CEO of Balanced Pharma.
To date, BPI has raised approximately $6.5 million and has completed $8 million of financing. After the completion of this round of financing, the company’s total investment will reach approximately $12 million, including more than $9 million from dentists and other dental professionals.
The company’s goals include providing multi-day pain relief to reduce the use of opioids after orthopedic and oral surgery, and developing faster, less painful and more reliable local anesthesia for dental procedures.
Balanced Pharma’s flagship products, BPI-001 and BPI-002, are modified versions of the injectable anesthetics lidocaine and articaine. Both improve hydrochloric acid balance, resulting in less pain, faster onset of action, and greater reliability.
The drugs will be packaged in standard dental cartridges, requiring no new equipment or clinical protocol changes. The company plans to launch BPI-001 in the U.S. in the fourth quarter of 2027, followed by BPI-002 and expansion into global markets. BPI estimates that the two products will compete in the $2.9 billion annual U.S. retail market.
Another product, BPI-004, is a non-opioid injectable analgesic composed of tetracaine (0.2%), lidocaine (0.4%), and epinephrine (1:250,000). When used during surgery, BPI-004 is designed to provide up to three days of pain relief with low toxicity, minimal motor dysfunction, and reduced reliance on opioids.
Balanced Pharma plans to bring BPI-004 to the U.S. market in the second quarter of 2025 under a 503(b) exemption. The company expects the drug to compete with bupivacaine and liposomal bupivacaine in the U.S. retail market, which has annual sales of $9 billion.
Developed by a dentist, BPI’s proprietary technology platform enables novel injectable anesthetic and analgesic drugs for a variety of applications, including orthopedics, general and oral surgery, and general dentistry.
Related topics:
